Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

CBC, Scarab Genomics form agreement to increase manufacturing yield of Solinex rhu-pGSN

Critical Biologics Corporation (CBC) and Scarab Genomics announced today a strategic agreement to substantially increase the manufacturing yield of CBC's lead therapeutic protein candidate, Solinex™, an intravenous formulation of recombinant human plasma gelsolin (rhu-pGSN).

30 Apr 2010

Communities with active participants demonstrate lower levels of crime, death rates

In a set of papers just published in two leading scholarly journals, LSU sociology professor Matthew Lee reports that both violent crime and all-cause mortality rates are on average substantially lower in communities with a vibrant civic climate.

30 Apr 2010

IPS examines how Uganda's anti-counterfeit bill could impact access to generic drugs

Inter Press Service examines Uganda's "controversial Counterfeit Goods Bill," which some say will limit the public's access to "life-saving generic medicines."

30 Apr 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 fiscal year (3QFY10).

30 Apr 2010

West Pharmaceutical Services reports 13.3% increase in first-quarter consolidated sales

West Pharmaceutical Services, Inc. today announced its results for the first quarter of 2010.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

BioTime to acquire Singapore-based company, ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that it has agreed to acquire the Singapore-based company ES Cell International Pte Ltd.

30 Apr 2010

Nutraceutical International reports net sales of $47.9M for second-quarter fiscal 2010

Nutraceutical International Corporation today reported results for the fiscal 2010 second quarter ended March 31, 2010. Net sales for the fiscal 2010 second quarter were $47.9 million compared to $42.0 million for the same quarter of fiscal 2009. For the second quarter of fiscal 2010, net income was $5.1 million, or $0.49 diluted earnings per share, compared to a net loss of $(23.4) million, or $(2.15) per diluted share, for the same quarter of fiscal 2009.

29 Apr 2010

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Labopharm Inc. and Gruppo Angelini today announced they have entered into an agreement to establish a joint venture in the United States for the commercialization of OLEPTRO, a novel once-daily formulation of the antidepressant trazodone approved by the U.S. Food and Drug Administration on February 3, 2010.

29 Apr 2010

Jiangsu Yanshen receives SFDA disciplinary notice for substandard quality human use rabies vaccine

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd. has received disciplinary notice from China's State Food and Drug Administration regarding its production of substandard quality human use rabies vaccine.

29 Apr 2010

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.

29 Apr 2010

ev3's first-quarter 2010 net sales up 21%

ev3 Inc., a global endovascular device company, today reported financial results for its fiscal first quarter and updated financial guidance for 2010. ev3's net sales totaled $123.9 million in the first quarter of 2010 compared to $100.4 million in the same quarter of the prior year. Excluding $2.9 million of positive impact due to foreign currency exchange rates, net sales increased 21% versus the prior year quarter.

29 Apr 2010

Cardiac Science responds to FDA communications on AED recall

Cardiac Science Corporation, responded to FDA communications released yesterday related to the AED recall first announced in November, 2009. The Agency communication specifies additional affected models and offers further guidance to users of AEDs affected by potential component defects in some of the Company's AEDs.

29 Apr 2010

Realton closes Series B financing

Realton Corporation, a pioneer in developing diode-pumped laser systems initially targeted to treat enlarged prostate, today announced the closing of its Series B financing co-led by OrbiMed Advisors and China Healthcare Partnership. Existing investor CSV Capital Partners will also participate in the financing. The financing will be used primarily to enhance Realton's marketing and distribution networks, expand its manufacturing capabilities and pursue new technology development.

29 Apr 2010

Geron reports net loss of $16.6M for first-quarter 2010

Geron Corporation today reported financial results for the three months ended March 31, 2010.

29 Apr 2010

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three months ended March 31, 2010, and filed its first quarter 2010 Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Apr 2010

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Salix Pharmaceuticals, Ltd. today announced the Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for GIAZO™ (balsalazide disodium) Tablets 1.1 g. for the treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

29 Apr 2010

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Targeted Genetics Corporation announced today that its licensing partner, Celladon Corporation, has reported today that Celladon's first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

29 Apr 2010

Neoprobe reports revenues of $2.7M for first-quarter 2010

Neoprobe Corporation, a diversified developer of innovative biomedical surgical oncology products, today announced consolidated results for the first quarter of 2010. First quarter 2010 revenues were $2.7 million, consistent with the record revenue reported for the first quarter of 2009.

29 Apr 2010

Manufacturing News and Research

Further Reading

REGN reports net loss of $30.5M for first-quarter 2010

CBC, Scarab Genomics form agreement to increase manufacturing yield of Solinex rhu-pGSN

Communities with active participants demonstrate lower levels of crime, death rates

IPS examines how Uganda's anti-counterfeit bill could impact access to generic drugs

Immunogen reports a net loss of $12.1 million in third quarter 2010

West Pharmaceutical Services reports 13.3% increase in first-quarter consolidated sales

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

BioTime to acquire Singapore-based company, ES Cell International

Nutraceutical International reports net sales of $47.9M for second-quarter fiscal 2010

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Jiangsu Yanshen receives SFDA disciplinary notice for substandard quality human use rabies vaccine

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

ev3's first-quarter 2010 net sales up 21%

Cardiac Science responds to FDA communications on AED recall

Realton closes Series B financing

Geron reports net loss of $16.6M for first-quarter 2010

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Neoprobe reports revenues of $2.7M for first-quarter 2010

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News